Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
More News related to CPRX
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- Catalyst (CPRX) Announces Organizational Changes and CEO McEnany's Term Extension
- Hapoalim Securities Upgrades Catalyst Pharmaceutical (CPRX) to Hold
- Morning Movers 10/05: DEPO, AVII, OPTV, CRXX, UCTT, CPRX Higher; FOLD, FTBK, SGEN, SCLN, REED Lower
More News related to Earnings
- Eastern Co. (EML) Reports Q4 GAAP EPS of $0.06
- National Financial Partners (NFP) Posts Q4 EPS of $0.61, Tops by 9c
- Integrated Electrical Services (IESC) Misses Street's Q1 Views
- American Financial (AFG) Reports Q4 Core EPS of $1.04, Beats by 6c; Raises FY10 Outlook
- Disney (DIS) Posts a Magical Q1
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) reports Q3 loss of $0.09, 2 cents better than the analyst estimate of ($0.11).
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
